MBOT vs. PROF, INFU, TLSI, ZJYL, SGHT, LNSR, HYPR, STIM, ECOR, and PDEX
Should you be buying Microbot Medical stock or one of its competitors? The main competitors of Microbot Medical include Profound Medical (PROF), InfuSystem (INFU), TriSalus Life Sciences (TLSI), Jin Medical International (ZJYL), Sight Sciences (SGHT), LENSAR (LNSR), Hyperfine (HYPR), Neuronetics (STIM), electroCore (ECOR), and Pro-Dex (PDEX). These companies are all part of the "medical equipment" industry.
Microbot Medical vs.
Profound Medical (NASDAQ:PROF) and Microbot Medical (NASDAQ:MBOT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment, valuation and community ranking.
In the previous week, Microbot Medical had 4 more articles in the media than Profound Medical. MarketBeat recorded 8 mentions for Microbot Medical and 4 mentions for Profound Medical. Microbot Medical's average media sentiment score of 0.30 beat Profound Medical's score of -0.15 indicating that Microbot Medical is being referred to more favorably in the news media.
47.9% of Profound Medical shares are held by institutional investors. Comparatively, 16.3% of Microbot Medical shares are held by institutional investors. 1.5% of Profound Medical shares are held by company insiders. Comparatively, 10.5% of Microbot Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Microbot Medical has lower revenue, but higher earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.
Profound Medical has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, Microbot Medical has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500.
Profound Medical presently has a consensus price target of $14.25, indicating a potential upside of 112.69%. Microbot Medical has a consensus price target of $9.00, indicating a potential upside of 352.26%. Given Microbot Medical's higher possible upside, analysts plainly believe Microbot Medical is more favorable than Profound Medical.
Microbot Medical received 308 more outperform votes than Profound Medical when rated by MarketBeat users. However, 72.73% of users gave Profound Medical an outperform vote while only 70.73% of users gave Microbot Medical an outperform vote.
Microbot Medical has a net margin of 0.00% compared to Profound Medical's net margin of -349.41%. Profound Medical's return on equity of -85.22% beat Microbot Medical's return on equity.
Summary
Microbot Medical beats Profound Medical on 10 of the 18 factors compared between the two stocks.
Get Microbot Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBOT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Microbot Medical Competitors List
Related Companies and Tools
This page (NASDAQ:MBOT) was last updated on 2/15/2025 by MarketBeat.com Staff